Critical issues in prevention and control of rheumatic fever and rheumatic heart disease

    Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


    The evidence base for public health and therapeutic interventions to prevent and control acute rheumatic fever (ARF) and rheumatic heart disease (RHD) still has some big gaps. Resolving critical issues in the pathogenesis of ARF should accelerate vaccine development and provide reassurances about vaccine safety. The basis of the genetic restriction of ARF predisposition and of the "immunogenic" determinants within group A streptococci (GAS) are critical to define. Also important is whether other bacteria such as groups C and G streptococci can be rheumatogenic and whether skin streptococci can cause ARF, either directly or via secondary throat colonization. Benzathine penicillin remains the mainstay of secondary prevention by preventing recurrent ARF and progression of RHD. However, there remain major issues of quality, supply, dosing, optimal timing of dosing and how best to incorporate secondary prophylaxis into primary care with either vertical or horizontal programs. Alternative secondary prophylaxis regimens remain to be developed. � 2006.
    Original languageEnglish
    Title of host publicationStreptococci
    Subtitle of host publicationNew Insights into an Old Enemy
    EditorsKS Sriprakash
    Place of PublicationAmsterdam
    Number of pages4
    ISBN (Print)444522050
    Publication statusPublished - 2006


    Dive into the research topics of 'Critical issues in prevention and control of rheumatic fever and rheumatic heart disease'. Together they form a unique fingerprint.

    Cite this